罗氏将完成15亿美元收购美国生物制药公司Poseida

智通财经
08 Jan

智通财经APP获悉,罗氏(RHHBY.US)周三表示,计划完成对美国生物制药公司Poseida Therapeutics(PSTX.US)的收购。据了解,Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示,已接受支付Poseida近6500万股股份,相当于该公司股票的66%,股东以每股9美元的价格出价,并额外支付每股高达4美元的或有付款。考虑到这一因素,该交易的价值将高达约15亿美元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10